Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia
TPN-101 treatment reduced the rate of decline of Vital Capacity by 50% compared to placebo after 24 weeks, an objective respiratory measure that correlates...